Longitudinal Study of the Porphyrias
NCT01561157
Recruiting
The objective of this protocol is to conduct a longitudinal multidisciplinary investigation of the human porphyrias including the natural history, morbidity, pregnancy outcomes, and mortality in people with these disorders.
Gender:
ALL
Ages:
1 minute and above
Trial Updated:
02/28/2025
Locations: University of Alabama, Birmingham, Birmingham, Alabama +14 locations
Conditions: Acute Porphyrias, Cutaneous Porphyrias
Register for Updates
Pilot Trial of Pregnenolone in Autism
NCT02627508
Recruiting
This is a research study to examine the tolerability and effectiveness of pregnenolone in individuals with autism. Pregnenolone is a naturally occurring steroid hormone in the brain that has been implicated in treating various psychiatric conditions. The investigators hope to learn the effects and safety of using pregnenolone in reducing irritability and sensitivity to sensory differences and improving social communication in individuals with autism. The investigators hope by studying the effect... Read More
Gender:
ALL
Ages:
Between 14 years and 25 years
Trial Updated:
02/28/2025
Locations: Stanford University School of Medicine, Stanford, California
Conditions: Autism Spectrum Disorder, Autism
Register for Updates
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors
NCT02715284
Recruiting
This is a multi-center, open-label, first-in-human Phase 1 study evaluating the anti-programmed death receptor 1 (anti-PD-1) antibody dostarlimab (also known as TSR-042) n participants with advanced solid tumors who have limited available treatment options. The study will be conducted in 2 parts with Part 1 consisting of safety evaluation, pharmacokinetics (PK), and pharmacodynamics (PDy) of escalating doses of dostarlimab. Dose escalation will be based on ascending weight-based dose levels (DLs... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: GSK Investigational Site, Birmingham, Alabama +129 locations
Conditions: Neoplasms
Register for Updates
Lumbar Drain Vs Extraventricular Drain to Prevent Vasospasm in Subarachnoid Hemorrhage
NCT03065231
Recruiting
Vasospasm is a common complication after rupture of intracranial aneurysms causing devastating neurologic deficits and death. Vasospasm has been directly associated with the amount of subarachnoid blood inside the basal cisterns. Prior literature has attempted to refine treatment of ruptured intracranial aneurysms but does not have clear guidelines on the optimal method to drain subarachnoid blood. Two methods, extraventricular drain (EVD) and lumbar drain (LD) have been compared retrospectively... Read More
Gender:
ALL
Ages:
Between 18 years and 110 years
Trial Updated:
02/28/2025
Locations: UCSD Medical Center, San Diego, California
Conditions: Vasospasm, Intracranial, Subarachnoid Hemorrhage
Register for Updates
The University of Alabama At Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy
NCT03457493
Recruiting
The primary objective of this substudy is to measure the concentration and the regional brain distribution of activated brain microglia/macrophages using the PET ligand \[18F\]DPA-714 in participants enrolled in the UAB Innate and Adaptive Immunity in Parkinson's Disease (Clinical Research Core) and Longitudinal \[18F\]DPA-714 Imaging in a Parkinson Disease Cohort studies. The PET tracer \[18F\]DPA-714 binds to the 18 kDa translocator protein (TSPO, also known as the peripheral benzodiazepine re... Read More
Gender:
ALL
Ages:
30 years and above
Trial Updated:
02/28/2025
Locations: UAB Advanced Imaging Facility, Birmingham, Alabama
Conditions: Parkinson Disease
Register for Updates
Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation
NCT03728335
Recruiting
This phase II trial studies the side effects of using enasidenib as maintenance therapy in treating patients with acute myeloid leukemia with IDH2 mutation following donor stem cell transplant. Enasidenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: City of Hope Medical Center, Duarte, California +1 locations
Conditions: Acute Myeloid Leukemia
Register for Updates
L-arginine to Reduce Sympathetic Nerve Activity in CKD Patients
NCT03982160
Recruiting
Chronic kidney disease (CKD) is associated with a higher risk of cardiovascular disease and death. An overactive sympathetic nervous system in CKD patients is one of the major mechanisms increasing the cardiovascular risks in this patient population. A potential signal driving sympathetic nerve activity (SNA) involves accumulation of the endogenous nitric oxide synthase (NOS) inhibitor asymmetric dimethylarginine (ADMA). ADMA is elevated in CKD and is a strong, independent predictor of future ca... Read More
Gender:
ALL
Ages:
Between 35 years and 75 years
Trial Updated:
02/28/2025
Locations: University of Delaware, Newark, Delaware +1 locations
Conditions: Chronic Kidney Disease
Register for Updates
Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients with Persistent Disease After Induction
NCT04049539
Recruiting
This phase II trial studies the side effects and how well Vyxeos works in treating patients with intermediate and high-risk acute myeloid leukemia who have failed an initial cycle of standard cytarabine and daunorubicin chemotherapy. Vyxeos is a combination of both chemotherapy drugs cytarabine and daunorubicin contained in a liposome. Drugs used in chemotherapy, such as cytarabine and daunorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stoppi... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/28/2025
Locations: UC Davis Comprehensive Cancer Center, Sacramento, California +1 locations
Conditions: Blasts More Than 5 Percent of Bone Marrow Nucleated Cells, Persistent Disease, Refractory Acute Myeloid Leukemia
Register for Updates
Natural History of Medullary Thyroid Cancer to Inform Advanced Disease Management
NCT04216732
Recruiting
This study utilizes a multi-institutional registry to describe the natural history of medullary thyroid cancer that has spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) in understanding disease management. The goal of this study is to learn about how medullary thyroid cancer develops and progresses.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: University of California San Francisco, San Francisco, California +1 locations
Conditions: Advanced Thyroid Gland Medullary Carcinoma, Stage III Thyroid Gland Medullary Carcinoma AJCC v8, Stage IV Thyroid Gland Medullary Carcinoma AJCC v8, Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8, Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8, Stage IVC Thyroid Gland Medullary Carcinoma AJCC v8
Register for Updates
Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
NCT04223765
Recruiting
This study will combine both T cells and antibodies in order to create a more effective treatment. The treatment tested in this study uses modified T-cells called Autologous T Lymphocyte Chimeric Antigen Receptor (ATLCAR) cells targeted against the kappa light chain antibody on cancer cells. For this study, the anti-kappa light chain antibody has been changed so instead of floating free in the blood, a part of it is now joined to the T cells. Only the part of the antibody that sticks to the lymp... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, North Carolina
Conditions: Mantle Cell Lymphoma, Follicular Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Nodal Marginal Zone Lymphoma, Indolent Non-hodgkin Lymphoma
Register for Updates
Study of RET Inhibitor TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities
NCT04683250
Recruiting
Phase 1 and 2 trial to study the safety, pharmacokinetics, and efficacy of TAS0953/HM06 in patients with advanced solid tumors with RET gene abnormalities. Phase 1 aims to determine the Maximum Tolerated Dose (MTD) and identify the Recommended Phase 2 Dose (RP2D) to be used in phase 2.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: Chao Family Comprehensive Cancer Center, Orange, California +16 locations
Conditions: RET-altered Non Small Cell Lung Cancer, RET-altered Solid Tumors
Register for Updates
Remote Monitoring and Management of Chemotherapy Induced Peripheral Neuropathy
NCT04763356
Recruiting
This is a prospective randomized trial designed to investigate a new care model for patients who suffer from nerve damage from chemotherapy called chemotherapy induced peripheral neuropathy (CIPN). All participants in the study will report their CIPN symptoms daily using a website, app or phone for 12 weeks. In one group the data will be collected and participants will be encouraged to reach out to their treating doctors for uncontrolled symptoms. These participants' doctors can prescribe any tr... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: University of Utah, Salt Lake City, Utah +2 locations
Conditions: Chemotherapy-induced Peripheral Neuropathy
Register for Updates